spite rigorous investigations, the molecular basis for the interplay among Hh, Ptch, and Smo remains unclear, and the structural basis for the recognition between Ptch and Hh is yet to be elucidated.
The 1447-residue human Ptch1 protein is predicted to contain 12 transmembrane segments (TMs) and to share structural similarity with the bacterial resistance-nodulation-division (RND) family transporters. TMs 2 to 6 of Ptch1 constitute the sterol-sensing domain (SSD), which has been found in several proteins involved in sterol transport and metabolism.
The molecular mechanism for potential sterol binding or transport activity of these SSDcontaining proteins remains elusive.
RATIONALE: To obtain a sample suitable for structural study, we generated several constructs of human Ptch1 based on sequence conservation and functional characterizations. Eventually, the truncated human Ptch1 containing residues 1 to 1305, which was transiently expressed in human embryonic kidney (HEK) 293F cells, exhibited a sufficient expression level and good solution behavior after affinity and size exclusion chromatography purification. Both oligomeric and monomeric states of Ptch1 were observed. The monomeric form was used for single-particle cryo-electron microscopy (cryo-EM) analysis because of its excellent behavior under cryo conditions.
Among the three mammalian Hh homologs Sonic (Shh), Desert (Dhh), and Indian (Ihh), Shh has been the prototype for functional and mechanistic investigations. The N-terminal domain of human Sonic Hh (ShhN, residues 24 to 197) expressed and purified in Escherichia coli was able to form a stable complex with the detergent-solubilized Ptch1 protein in the presence of cholesteryl hemisuccinate (CHS).
RESULTS:
The cryo-EM structures of human Ptch1 alone and in complex with ShhN were determined at overall resolutions of 3.9 Å and 3.6 Å, respectively. Two interacting extracellular domains, ECD1 and ECD2, and 12 TMs are resolved for Ptch1. ECD1 and ECD2 move toward each other upon arrival of ShhN and together constitute the docking site for ShhN. Detailed recognition between ShhN and Ptch1 was analyzed and biochemically confirmed.
Two elongated densities, both consistent with CHS, are observed in Ptch1 with or without ShhN, one in a pocket enclosed by the ECD domains and the other in a membrane-facing cavity of the SSD. Structure-guided biochemical analyses revealed steroid-dependent interaction between ShhN and Ptch1. The structure of a steroid binding-deficient Ptch1 mutant displays pronounced conformational rearrangements relative to the wild-type protein.
CONCLUSION: The structures of human Ptch1 and its complex with ShhN reveal the molecular basis for the recognition between Ptch1 and ShhN. The identification of two steroid-binding sites in Ptch1 establishes an important framework for future investigations of Hh signaling and provides critical insight into sterol perception by SSD-containing proteins.
T he Hedgehog (Hh) signaling pathway, which has been investigated extensively in Drosophila and vertebrates, plays a pivotal role in embryogenesis and postnatal tissue maintenance and regeneration (1) (2) (3) (4) (5) . Activation of Hh signaling is initiated by binding of the secreted protein Hh to the membrane-embedded receptor Patched (Ptch) in Hh-responsive cells (6) (7) (8) . In the absence of Hh, Ptch inhibits Smoothened (Smo), a class F GPCR (G protein-coupled receptor), although the mechanism remains unclear (9) (10) (11) . Binding of Hh to Ptch relieves the inhibition on Smo and turns on the signaling events that lead to the transcriptional activation of the Hh pathway (12) (13) (14) (15) (16) (17) . Compromised Hh pathway activity may result in birth defects, whereas aberrant activation of Hh signaling by suppressing Ptch or activating Smo has been implicated in tumorigenesis of several tissues, as exemplified by basal cell carcinoma and medulloblastoma (18) (19) (20) (21) (22) .
In mammals, three Hh homologs have been identified-Sonic (Shh), Desert (Dhh), and Indian (Ihh)-among which Shh represents the prototype for functional and mechanistic elucidation (5) . A~450-residue Shh precursor undergoes autocatalytic cleavage and yields an N-terminal domain (ShhN) of~20 kDa that is responsible for all known signaling activities. ShhN is modified with N-terminal palmitoyl and C-terminal cholesteryl moieties (23) (24) (25) (26) (27) . Although unpalmitoylated ShhN exhibits decreased activity (26, 28) , these modifications are dispensable for the highaffinity binding to Ptch (29) .
Because abnormal activation of the Hh pathway is associated with tumorigenesis, different types of inhibitors have been developed that target Hh signaling (30, 31) (fig. S1 ). Most of these are antagonists for Smo or inhibitors of downstream components in the Hh pathway. However, some of them are designed to disrupt the interaction between Ptch1 and ShhN, such as Robotnikinin (32) and HL2-m5 macrocyclic peptide (33) (fig. S1 ). Structural information on the ShhN-Ptch1 complex may provide important insight into design or optimization of ligands to disrupt the formation of a complex between ShhN and Ptch1. Whereas a number of crystal structures of ShhN segments alone and in complex with different binding proteins have been reported (34) , there has been a lack of structural information on Ptch.
Patched (ptc) was cloned as a segment-patterning gene in Drosophila (35, 36) . The human homolog was later identified as a tumor suppressor for basal cell nevus syndrome (also known as Gorlin syndrome) (37, 38) . There are two Ptch homologs in mammals, Ptch1 and Ptch2, both of which, despite their divergent expression patterns and physiological functions, bind to the three types of mammalian Hh ligands with similar affinity (39, 40) . The full-length human Ptch1 (hPtch1), consisting of 1447 amino acids, is predicted to contain 12 transmembrane segments (TMs), two extracellular domains (ECDs), and two intracellular domains (37) . Ptch proteins share sequence similarity with the bacterial resistance-nodulationdivision (RND) family transporters exemplified by the proton-driven multidrug resistance pump AcrB (41, 42) . TMs 2 to 6 of Ptch constitute the sterolsensing domain (SSD) that has been found in a number of sterol transport and metabolism-related proteins, such as 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGCR), SREBP cleavageactivating protein (SCAP), Niemann-Pick type C1 (NPC1), NPC1-like 1 (NPC1L1), and another Hh signaling component, Dispatched (Disp) (43) . Although the structures of human NPC1 have recently been determined, the molecular mechanism of potential sterol binding or transport mediated by the SSD-containing proteins remains enigmatic (44, 45) .
Here, we report the cryo-electron microscopy (cryo-EM) structures of human Ptch1 alone and in complex with ShhN at overall resolutions of 3.9 Å and 3.6 Å, respectively. The structures reveal the detailed recognition between ShhN and Ptch1. Unexpectedly, two steroid molecules are observed, one in a pocket enclosed by the ECDs and one in the membrane-facing cavity of the SSD. Structure-guided biochemical analyses suggest that the interaction between ShhN and Ptch1 is steroid-dependent-an observation corroborated by additional structural evidence.
Structural determination of human Ptch1 and the Ptch1-ShhN complex
To obtain a sample suitable for structural study, we generated several constructs of human Ptch1 based on sequence conservation and functional characterizations ( fig. S2) (8, 46, 47) . Consistent with a previous observation in a cell-based binding assay that the C terminus-truncated mouse Ptch1 binds to ShhN with affinity similar to that of wild-type Ptch1 (Ptch1-WT) (8) , the C terminal intracellular domain of mouse Ptch1 was shown to be dispensable for Ptch1-dependent regulation of canonical Hh signaling (46, 47) . We therefore tested a number of C-terminus truncations and identified an optimal construct for human Ptch1 (residues 1 to 1305) that exhibited sufficient expression level and good solution behavior ( fig. S3 ).
[See below for details of the subcloning, transient human embryonic kidney (HEK) 293F cell expression, purification, and cryo-EM data acquisition of Ptch1.] Consistent with the reported oligomerization of Ptch1 (47, 48) , recombinant Ptch1 eluted in two peaks upon size-exclusion chromatography (SEC), suggesting distinct oligomerization states ( fig. S3B ). Preliminary assessment using cryo-EM showed that protein particles in the earlier peak were heterogeneous, posing a major challenge for structural determination. In contrast, the proteins in the later peak, despite its smaller size, appeared homogeneous and displayed multiple orientations in the thin layer of vitreous ice. We therefore focused on the monomeric form of Ptch1 for cryo-EM analysis.
An EM reconstruction was obtained at 3.9 Å resolution from 94,445 selected particles ( fig. S3C ) according to the gold-standard Fourier shell correlation 0.143 criterion. Although the construct used for structural determination contains 1305 residues, all the intracellular segmentsincluding the 72 residues on the N terminus, residues 608 to 730 that connect TMD1 (TMs 1 to 6) and TMD2 (TMs 7 to 12), and the C-terminal segment after Ser
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-are invisible, likely owing to intrinsic flexibility. In total, 990 residues were built with 969 side chains assigned (Fig. 1A , Table 1 , and figs. S4A, S5A, and S6A).
The well-resolved regions include two ECDs and the 12 TMs that display a typical RND family architecture with a two-fold pseudosymmetry around an axis that is perpendicular to the membrane (Fig. 1A and fig. S7A ) (44, 49) . The two TMDs, each preceded by an amphiphilic helix that lies on the intracellular boundary of the membrane (designated IH), can be superimposed with a root mean square deviation (RMSD) of 3.7 Å over 186 Ca atoms ( fig. S7B ).
The two ECDs in Ptch1, ECD1 between TM1 and TM2 and ECD2 between TM7 and TM8, correspond to domain C and domain I in NPC1, respectively (44) . Each ECD is linked to the N-terminal TM by a long linker (linker 1 for ECD1 and linker 7 for ECD2) and to the C-terminal TM by a Neck helix (Fig. 1A and fig. S7C ). ECD1 and ECD2 both contain a topologically similar core region right above the TMD, which we term the "base domain" (Fig. 1A and fig. S7 , C and D). Despite similar folds of the two base domains, ECD1 and ECD2 display divergent spatial arrangements and cannot be well superimposed ( fig. S7D ).
On top of the base domains, ECD1 and ECD2 each contain an extra helical domain that is absent in NPC1 (Fig. 1A) . Notably, both ECDs are enriched in lengthy loops ( fig. S7C ). For instance, the segment (residues 943 to 969) that connects b2 and b3 in the base domain of ECD2 forms an upward-extending loop hairpin (designated the H loop) that represents part of the helical domain (figs. S2 and S7, A and C). The two ECDs interact with each other through an extended 2 of 11 respectively. All structure figures were prepared using PyMol (81). yet loose interface and both project into the extracellular space with similar heights of approximately 80 Å (Fig. 1A) . Six glycosylation sites were observed, four on ECD1 and two on ECD2 ( fig. S7C ). For structural determination of the complex between Ptch1 and ShhN, we overexpressed human ShhN (residues 24 to 197) in Escherichia coli and incubated the purified protein with the C terminus-truncated human Ptch1 for cryo-EM analysis. (See below for details of the reconstitution, sample preparation, and cryo-EM data acquisition of the Ptch1-ShhN complex.) A total of 137,823 selected particles yielded a reconstruction at 3.6 Å resolution, which contains density for ShhN (Fig. 1B, Table 1 , and figs. S4B and S5B). The crystal structure of ShhN (PDB code 4C4M) was docked into the density with manual adjustment. Residues 39 to 190 of ShhN were resolved (Fig. 1B) . The improved resolution allows more accurate structural modeling of Ptch1 (Fig. 1B  and fig. S6 , B and C). Most of the structural descriptions hereafter are based on the complex structure if not otherwise noted.
Ramachandran plot statistics (%)
Interface between Ptch1 and ShhN ShhN binds to the Ptch1 surface constituted by the upper helical domains of the two ECDs ( Fig.  2A ). An extended loop (residues 206 to 213) on ECD1 designated the E loop (because it contains the conserved Glu 212 ) ( fig. S2 ), the ensuing helix a3 on ECD1, and the H loop on ECD2 constitute the primary binding site for ShhN (Fig. 2A) .
In addition to Ptch and Smo, Hh signaling is subject to regulation by cell surface or extracellular proteins, such as the co-receptors Cdon/ Boc (equivalent of Ihog/Boi in invertebrates), the extracellular Hh antagonist Hhip (Hh interacting protein), and the antagonist antibody 5E1 (34) . ShhN, which shares structural homology to a bacterial carboxypeptidase but lacks hydrolytic activity, contains a Lys/Arg-enriched pseudo-active site groove that represents the primary surface for many binding proteins (8) . Examination of the structure of the Ptch1-ShhN complex reveals that the Ptch1-interacting surface, which involves the pseudo-active site groove, overlaps with that for other binding proteins, including the FNIII repeat of Cdo (CdoFn3), Hhip, and 5E1 Fab (fig. S8 ). The structure thus provides the basis for the observed competitive binding for Hh by Ptch1 and several binding proteins (50) (51) (52) (53) .
The ShhN-Ptch1 interface is primarily mediated by polar and charged residues (Fig. 2B ). ECD1 and ECD2 each contribute multiple acidic residues for interaction with the Lys/Arg patch that lines the pseudo-active site groove of ShhN. The reported resolution for the interface is approximately 3.8 Å (Fig. 1B) (Fig. 2B, right) .
The structural observation was verified by mutational analysis. We used wild-type or mutated ShhN proteins that were fused to MBP as bait to pull down Ptch1 variants (Fig. 2C) . Single point mutations of the aforementioned ShhN or Ptch1 residues to opposite charges or double mutations to Ala all resulted in compromised complex formation. As a control, Ala substitution of ShhN-Thr 77 (T77A), which is not engaged in Ptch1 interactions, had no effect on Ptch1 binding (Fig. 2C ).
An extracellular steroid-binding site in Ptch1
Structural comparison of Ptch1 in the absence and presence of ShhN reveals marked shifts of Gong The morph was generated by aligning the two structures and generating 60 intermediates in Chimera. The morphs were merged and displayed in PyMol using the "mset" command.
the (Fig. 3A) . Helix a1, which connects to TM1 via linker 1, swings together with ECD2 (Fig. 3A, left) . The lengthy linker 1 and the C-terminal short loop that connect the Neck helix to the TMD may confer the structural plasticity for the observed domainwise swing motions. Note that whereas the residues in the E loop in ECD1 are well resolved in the Ptch1-ShhN complex, even the backbone of the corresponding segment is broken in the map for Ptch1 alone, which suggests that this segment is stabilized by ShhN (Fig. 3B) .
In addition to accommodating ShhN, the E loop covers a pocket on the interface of ECD1 and ECD2. Unexpectedly, a stretch of density is observed in this elongated pocket in both EM reconstructions with or without ShhN (Fig. 3, C  and D, and fig. S6D ). In the EM map for the Ptch1-ShhN complex (3.6 Å resolution), the density sealed between ECD1 and ECD2 is better defined and has a size and shape consistent with a cholesteryl hemisuccinate (CHS) molecule. The CHS molecule is localized on the interface between the upper helical domains of the two ECDs, where ECD1 provides the primary coordination. Nearly 20 hydrophobic residues on the E loop and helices a3, a6, and a7 from ECD1 form the contour of the pocket for CHS, whereas ECD2 only engages two small hydrophobic residues, Val 932 and Ala 935 , on its helix a7 (Fig. 3D) . Although CHS appears to be sealed within the ECDs, it was in the buffer used for protein extraction, suggesting dynamic access to this extracellular steroid-binding site (ESBS). As the E loop and helix a3 on ECD1 are also the major constituents of the docking site for ShhN (Fig. 2B), Gong et al., Science 361, eaas8935 (2018) 10 August 2018
4 of 11 the different quality of the EM maps for this region with or without ShhN suggests that binding of ShhN may restrict the motion of these gating elements, hence potentially limiting the access to or exit from the ESBS.
Coordination of the steroidal moiety by the SSD
A similar stretch of density is found in a surface cavity on the membrane-facing side of the SSD.
Although the size and shape of the density are also consistent with a CHS, we cannot exclude the possibility that it may belong to an endogenous molecule or a digitonin (Fig. 4A) . The hydrophobic composition and the V shape of the SSD cavity define the orientation of the bound ligand. We modeled a CHS molecule into the density. A number of conserved hydrophobic residues on TMs 2 to 4 of the SSD shape the cavity that accommodates the cholesteryl moiety (Fig. 4A, insets, and fig. S9 ).
Although the ligand seems to bind to a similar location as the computationally predicted docking site on the SSD of NPC1 (45), the exact position and detailed coordination may be different. The SSDs exhibit considerable conformational divergence between Ptch1 and NPC1 (Fig. 4B) . In both proteins, a well-characterized Pro residue (Pro 691 in NPC1 and Pro 504 in Ptch1) maps to the bottom of the SSD pocket and directly participates in the ligand interaction (Fig. 4C and fig.  S9A ). The single point mutation Pro 691 → Ser, which is a disease mutation associated with Niemann-Pick disease type C, was shown to eliminate the cross-linking of NPC1 with the compound U18666A, a steroid blocker for NPC1-mediated cholesterol egress (54) . Ptch1-P504L (Pro 504 → Leu) is associated with Gorlin syndrome (55) . Structural analysis of Ptch1 suggests that substitution of the Pro with a polar residue (Ser) or a bulky residue (Leu) may alter the chemical environment or change the contour of the pocket, hence making it less favorable for accommodating a cholesteryl moiety (Fig. 4, A and C) .
The interaction between ShhN and Ptch1 is ligand-dependent
To validate the structural observations and to investigate the functional relevance of the bound steroid ligands, we generated three Ptch1 variants with point mutations designed to disrupt Gong steroid binding: Ptch1-L282Q (Leu 282 → Gln), where the hydrophobic residue within the ESBS is replaced by a polar one (Fig. 3D) ; Ptch1-T500F/ P504L (Thr 500 → Phe and Pro 504 → Leu), in which the substitution with bulky residues may interfere with steroid binding to the SSD (Fig.  4A, right inset) ; and Ptch1-3M (with all three of these point mutations). It is difficult to directly measure the affinities between steroid molecules and the Ptch1 variants because of the interference by the detergent micelles. We therefore sought to solve the structures of Ptch1 variants using protocols identical to those for wild-type proteins.
Because the Ptch1-ShhN complex exhibits better resolution, we had planned to solve the structure of the complex. However, complex formation was markedly compromised between ShhN and all three Ptch1 variants. In particular, Ptch1-3M could be pulled down only minimally by MBPShhN (Fig. 5A) . To semiquantitatively compare the affinity with ShhN between these variants and Ptch1-WT, we performed a concentration gradient titration of Ptch1 proteins (Fig. 5B) . The affinity for ShhN of the ESBS mutant L282Q and the SSD mutant T500F/P504L appeared to be weakened by factors of approximately 16 and 4, respectively, whereas that of Ptch1-3M was reduced by more than a factor of 64. This observation seems to suggest a synergistic effect on the interaction with ShhN by the two steroidbinding sites (Fig. 5B) .
To validate that the reduced ShhN binding was indeed related to steroid binding, we next examined the effect of CHS on complex formation (Fig. 5C ). Ptch1 purified with n-dodecyl-b-Dmaltopyranoside (DDM) barely interacted with ShhN, whereas addition of CHS restored complex formation (Fig. 5C, lanes 1 and 2) . CHS was also required for ShhN binding when Ptch1 was purified with the detergents C 12 E 8 or Cymal-6, which have distinct polar and hydrophobic moieties (Fig. 5C, lanes 3 to 6) . In contrast, digitonin was sufficient to support complex formation (Fig. 5C, lane 7) .
Taken together, our biochemical analyses suggest that complex formation between ShhN and Ptch1 may depend on the steroid ligand. To elucidate the molecular basis for this biochemical discovery, we focused on the structural determination of Ptch1-3M.
Pronounced conformational changes of Ptch1 upon steroid binding
The protocol for purification and data collection of Ptch1-3M is identical to that of Ptch1-WT. The numbers of the initial (>3.3 million) and selected (154,721) particles for 3D map reconstruction were both higher than that for Ptch1-WT alone and in complex with ShhN (Table 1) ; however, the final resolution was 4.1 Å for the overall structure of Ptch1-3M (figs. S4C, S5A, and S10A). As anticipated, the densities corresponding to CHS in the ESBS and SSD diminished, confirming the disrupted steroid binding by these point mutations (Fig. 6A) .
Surprisingly, the overall structure of Ptch1-3M undergoes striking rearrangements from that of the wild-type protein (Movie 2). When the two structures are overlaid relative to the SSD, both TMD1/2 and ECD1/2 undergo marked twists (Fig. 6B ). Individual domain comparison shows minor interdomain shifts between the two ECDs ( Fig. 6C and Movie 2). Within ECD1, the E loop, whose backbone exhibits broken density in Ptch1-WT alone (Fig. 3B) , is invisible in Ptch1-3M, indicating increased flexibility in the absence of CHS (Fig. 6A) . Meanwhile, helix a3 moves toward the pocket (Fig. 6C) . The resolution of the ECDs in Ptch1-3M is also considerably lower than that in Ptch1-WT ( fig. S10 ), suggesting increased overall mobility. Because ECD1 and ECD2 need to move closer to form the ShhN docking site (Fig. 3A) , the increased flexibility of the ECDs, particularly of the E loop and helix a3, may account for the reduced binding affinity with ShhN when the ESBS is not occupied by a steroid ligand.
Structural comparison of Ptch1-3M and Ptch1-WT affords an opportunity to investigate how the SSD senses sterol. Because none of the three residues Leu 282 , Thr 500 , or Pro 504 is involved in intraprotein interaction, the structural shifts from Ptch1-3M (steroid-free) to Ptch1-WT (steroid-bound) may be interpreted as the conformational changes induced by arrival of the steroid ligand.
Binding of the steroid molecule to the SSD causes Neck helix 2, TM2, and TM4 to tilt toward the ligand (Fig. 6, D and E, and Movie 2). Such conformational shifts are similar to those observed in the structural comparison between ligand-free NPC1 and Ptch1-WT (Fig. 4, B and C) . However, the pronounced relative rotation of the two TMDs around an axis that is perpendicular to their interface is unexpected (Fig. 6D , left, and Movie 2). Detailed structural comparison of Ptch1-3M and Ptch1-WT reveals the interdomain interactions that underlie the coupled conformational changes of TMD1/2 and ECD1/2 (Fig. 6, B and D, and Movie 3).
The short linker between TM5 and TM6 shifts concertedly with TM4 upon steroid binding (Fig.  6E ) and pulls along linker 1 and helix a1 in ECD1. The motion of helix a1 induces the domainwise motion of ECD2 (Fig. 6C and Movie 3) . The two base domains and the short linker between TM11 and TM12 move concomitantly with Neck helix 2 through extensive interactions (Movie 3).
The coupled movements of the four domains, TMD1/2 and ECD1/2, predict that mutations in one domain may alter an event in another domain through allosteric action. Supporting this notion, lack of steroid binding to SSD may result in increased flexibility of the two ECDs, hence leading to reduced ShhN binding (Fig. 5, A The interaction between purified Ptch1 and ShhN appears to be steroid-dependent. Ptch1 was purified in distinct detergents as indicated. CHS is required to retain the interaction when DDM, Cymal-6, or C 12 E 8 was used for Ptch1 purification. Ptch1 purified in digitonin forms a complex with ShhN in the absence of CHS.
7 of 11 (Asp 513 → Tyr), both of which are severe oncogenic mutations associated with Gorlin syndrome (56-58)-also exhibited reduced ShhN binding (Fig. 5A, lanes 5 and 6) . Gly 509 and Asp 513 are localized in the middle segment of TM4 and mapped to the interface with TMD2 (Fig. 6F) . As TM4 provides the primary site for steroid binding to SSD, these point mutations on the TMD2-facing side of TM4 may trap Ptch1 in a conformation that is incompatible for steroid binding to its SSD.
Discussion
Structural implications for steroid perception by SSD SSD-containing proteins are associated with cholesterol metabolism and transport (43) . For instance, SCAP is a key player in the sterol regulatory element-binding protein (SREBP) pathway that controls the cellular homeostasis of sterol (59), HMGCR catalyzes the rate-limiting step of cholesterol synthesis (60) , and NPC1 is essential for cholesterol egress from the lysosomes and late endosomes to other cellular compartments (61). However, direct evidence for sterol binding by the SSD has been missing. We find that Ptch1 possesses two sites that can accommodate steroid molecules, one within the ECDs and the other on the SSD. Structural comparison of the ligand-free Ptch1-3M and CHS-bound Ptch1-WT reveals the conformational changes of the SSD as well as the overall structure upon CHS binding (Fig. 6) . Also considering the structural differences of the SSDs between the ligand-free NPC1 and CHSbound Ptch1 (Fig. 4C) , the CHS-induced conformational changes observed here may represent a paradigm that SSD-containing proteins use for sterol perception.
Potential cross-talk between the ESBS and SSD
Although the steroid binding to the SSD was anticipated, the extracellular steroid-binding site in Ptch1 and the steroid-dependent binding between Ptch1 and ShhN were not. An immediate question concerns the source of this trapped steroid. Because of its highly hydrophobic nature, a free cholesterol would be unlikely to diffuse into this site directly from the aqueous milieu, unless it is a cholesterol derivative with increased water solubility. There are then three possible sources for a hydrophobic steroid molecule: (i) It may be delivered by a NPC2-like lipid transfer 8 of 11 protein, (ii) it may come from a steroidal moiety on a posttranslationally modified protein, or (iii) it may be extracted from the membrane and transferred to the ESBS by Ptch1 itself. Although option 1 is formally possible, there has been no report on extracellular lipid-transfer proteins for Ptch1. With respect to option 2, the C-terminal Gly 197 of ShhN is modified by a cholesteryl moiety, which can be a potential source. However, the last visible residue on the C terminus of ShhN is Ser 190 , and a seven-residue peptide, even in a completely extended conformation, is not long enough to deliver the cholesteryl moiety to the ESBS in cis (Fig. 7A) . In addition, in the structure of Ptch1 alone, the ESBS may allow a peptide to be connected to the steroid ligand; however, the sealed ESBS can hardly accommodate such a peptide in the Ptch1-ShhN complex (Fig. 7A) . Therefore, we do not favor possibility 2.
Ptch1 has been speculated to be a transporter given its structural similarity with the RND pumps (9) . A recent study discovered that Ptch1-mediated inhibition of Smo depends on extracellular Na + (62) . Furthermore, the GxxxD(D) motif on TM4 and similar Gxxx(E/D) motif on TM10, which are required for the cotransport activity of the bacterial RND transporters, are conserved in Ptch1 (Fig. 6 , E and F) (9, 63) . Consistent with steroid transport, ECD1 and ECD2 of Ptch1 encompass a tunnel that connects the ESBS and SSD in the absence of ShhN (Fig. 7B) . It remains to be investigated whether a steroid molecule can be transferred between these two sites, and if so, whether this tunnel provides the diffusion path (Fig. 7C) .
Structural implications for Hh signaling
Despite decades of rigorous characterization, the molecular mechanism for the inhibition of Smo by Ptch1 and the release of the inhibition by ShhN remains enigmatic. There are several outstanding questions. For instance, if Ptch1 functions as a sterol transporter, the transport activity is yet to be established. In addition, the abundance of cholesterol or its derivatives in primary cilia where Ptch1 inhibits Smo is unclear (64) . Despite these and other outstanding questions, the three structures presented here reveal that Ptch1 undergoes steroid-induced conformational changes while binding of ShhN locks Ptch1 in one conformation (Fig. 7C) . These findings lead us to speculate that the steroid-dependent structural shifts of Ptch1 may be required for its suppression of Smo, and that ShhN may inhibit Ptch1 by blocking this conformational change.
Many fundamental questions remain with regard to the function and mechanism of Ptch1 and ShhN. For instance, the unpalmitoylated ShhN used in this study is less active than the palmitoylated form in a cell-based assay by a factor of 30 to 40, although it retains high affinity with Ptch1 (26, 65) . What is more intriguing, a palmitoylated N-terminal 22-residue peptide was recently shown to activate Hh signaling in a cell-based assay (66) , which cannot be explained by the three structures. Palmitoylate may interfere with the conformational changes or steroid-binding ability of Ptch1. Another question concerns the endogenous ligand or substrate for Ptch1. The composition and contour of the ESBS and the SSD cavity both allow accommodation of cholesterol with orientations similar to that of the CHS in the structure (Fig. 7A ). Cholesterol derivatives with small-size modifications at C3-OH may also be compatible. The endogenous ligand(s) for Ptch1 may also act as agonists or antagonists for Smo. The structures reported here provide the basis for docking or simulation analysis that may facilitate the identification of such ligands. Finally, the structures of Ptch1 and ShhN presented here are both of monomers. The functional relevance of their oligomeric form remains unclear.
Despite these questions, the structures of human Ptch1 and its complex with ShhN set an important framework for future investigation of Hh signaling initiation and provide insight into the functional mechanism of SSD-containing proteins.
Materials and methods

Protein expression and purification
The complementary DNA of human Ptch1 (Uniprot: Q13635; residues 1 to 1305) was subcloned into the pCAG vector with an N-terminal FLAG tag and a C-terminal His 10 tag. The Ptch1 mutants were generated with a standard 2-step PCR-based strategy. When the HEK293F cell density reached 2.0 × 10 6 cells per ml, the cells were transiently transfected with the expression plasmids and polyethylenimines (PEIs) (Polysciences). Approximately 1 mg of plasmids were premixed with 3 mg of PEIs in 50 ml of fresh medium for 15 to 30 min before application. For transfection, 50 ml of mixture was added to 1 liter of cell culture and incubated for 30 min. Transfected cells were cultured for 48 hours before harvest. For purification of WT Ptch1 and its variants, the HEK293F cells were collected and resuspended in the buffer containing 25 mM Tris pH 8.0, 150 mM NaCl, and protease inhibitor cocktails (Amresco). After sonication on ice, the membrane fraction was solubilized at 4°C for 2 hours with 1% (w/v) DDM (Anatrace) and 0.2% CHS (Anatrace). For biochemical assays reported in Fig. 5C , the protein was extracted using 1% (w/v) indicated detergents in the absence or presence of 0.2% CHS. After centrifugation at 20,000g for 1 hour, the supernatant was collected and applied to antiFlag M2 affinity resin (Sigma). The resin was rinsed with wash buffer (W1 buffer) containing 25 mM Tris pH 8.0, 150 mM NaCl, 0.06% digitonin (w/v) (Sigma) or two critical micelle concentrations (CMC) of the other detergents with/ without CHS as indicated in Fig. 5C , and protease inhibitors. The protein was eluted with W1 buffer plus FLAG peptide (200 mg/ml). The eluent was then applied to the nickel affinity resin (Ni-NTA, Qiagen). After three times of rinsing with W1 buffer plus 20 mM imidazole, the protein was eluted from the nickel resin with W1 buffer plus 250 mM imidazole. The eluent was then concentrated and further purified by SEC (Superose 6 10/300 GL, GE Healthcare) in buffer containing 25 mM Tris pH 8.0, 150 mM NaCl, and 0.06% digitonin or two CMC of the other detergents with/without CHS as indicated in Fig. 5C . Ptch1 proteins were eluted in two peaks, which were separately pooled and concentrated for EM and biochemical analysis. The later peak corresponding to monomer was pooled and concentrated to~15 mg/ml for cryo sample preparation. The former peak corresponding to oligomer was used for the pull-down assay for different detergents as shown in Fig. 5C , whereas the latter peak was used for all the other pull-down assays.
The complementary DNA of human Shh (Uniprot: Q15465) N-terminal domain (ShhN, residues 24 to 197) was subcloned into the pET15 vector with N-terminal His 6 or MBP tags. The ShhN mutants were generated with a standard PCR-based strategy. The expression plasmids were transformed into E. coli BL21 (DE3) strain and protein overexpression was induced by 0.2 mM isopropyl b-D-thiogalactoside at an OD 600nm of 1.0. After growing at 20°C for 16 hours, the cells were collected and homogenized in buffer containing 25 mM Tris pH 8.0 and 150 mM NaCl. After sonication and centrifugation, the supernatant was applied to Ni-NTA affinity resin or amylose resin (New England Biolabs) and further purified by ion-exchange chromatography (Source 15S, GE Healthcare) and SEC (Superdex 200 10/300 GL, GE Healthcare). The peak fractions were pooled and concentrated for structural and biochemical analysis.
The Ptch1-ShhN complex was reconstituted by incubating the purified and concentrated Ptch1 and ShhN at a mass ratio of approximately 2:1 at 4°C for 1.5 hours before cryo-sample preparation.
Cryo-EM sample preparation and data collection
The cryo grids were prepared using Thermo Fisher Vitrobot Mark IV. The Quantifoil R1.2/ 1.3 Cu grids were glow-discharged with air for 30 s at medium level in Plasma Cleaner (Harrick Plasma, PDC-32G-2). Aliquots of 3.5 ml of purified Ptch1-WT, Ptch1-3M, or Ptch1-ShhN complex were applied to glow-discharged grids. After being blotted with filter paper for 4.0 s, the grids were plunged into liquid ethane cooled with liquid nitrogen. A total of 3983 micrograph stacks for Ptch1-WT, 6680 micrograph stacks for Ptch1-3M, and 4221 micrograph stacks for Ptch1-ShhN complex were automatically collected with AutoEMation II (67, 68) on Titan Krios at 300 kV equipped with K2 Summit direct electron detector (Gatan), Quantum energy filter (Gatan), Cs corrector (Thermo Fisher), and Volta phase plate (Thermo Fisher) at a nominal magnification of 105,000× with a fixed defocus value of -0.7 mm. Each stack was exposed in superresolution mode for 5.6 s with an exposing time of 0.175 s per frame, resulting in 32 frames per stack. The total dose rate was about 50 e -/Å 2 for each stack. The stacks were first motioncorrected with MotionCorr (69) and binned 2-fold, resulting in a pixel size of 1.091 Å/pixel.
The output stacks from MotionCorr were further motion-corrected with MotionCor2 (70); meanwhile, dose weighting was performed (71) . The defocus values were estimated with Gctf (72).
Cryo-EM data processing
For the Ptch1-WT dataset, a total of 1,710,446 particles were automatically picked with RELION 2.0 (73). After 2D classification, a 3D initial model was built from typical 2D class averages with e2initialmodel.py (74) . A total of 736,934 particles were selected from 2D classification and subjected to a global angular search 3D classification with one class and 40 iterations. The outputs of the 33rd to 40th iterations were subjected to local angular search 3D classification with four classes separately. A total of 516,223 particles were selected by combining the good classes of the local angular search 3D classification, yielding a 3D reconstruction with an overall resolution of 6.1 Å after 3D auto-refinement. The handedness of the 3D reconstruction was checked and corrected. Then 156,723 particles were selected after 3D classification against one good reference and four bad references, giving rise to improved resolution at 4.4 Å after 3D auto-refinement. Finally, a subset of 94,445 particles were further selected by "skip alignment" 3D classification with an adapted mask, yielding overall resolution of 3.9 Å after 3D auto-refinement. The procedure for data processing of the Ptch1-3M was the same as that for Ptch1-WT. Eventually a subset of 154,721 particles was selected to generate a 3D reconstruction with overall resolution of 4.1 Å. The procedure for data processing of the Ptch1-ShhN complex was similar with that for Ptch1 alone. To be brief, 1,518,460 particles were automatically picked. 2D classification resulted in 716,512 good particles that were subjected to subsequent global angular search 3D classification and local angular search 3D classification. After combining the good classes, 435,942 particles yielded a 3D reconstruction with overall resolution of 5.6 Å. After 3D classification against one good reference and four bad references, 137,823 particles were selected and gave rise to a 3D reconstruction of 4.4 Å resolution, which was further improved to 3.6 Å by applying an adapted mask during 3D auto-refinement.
All 2D classification, 3D classification, and 3D auto-refinement were performed with RELION 2.0. Resolutions were estimated with the goldstandard Fourier shell correlation 0.143 criterion (75) with high-resolution noise substitution (76) .
Model building and refinement
The Ptch1-ShhN complex map at 3.6 Å was used for de novo model building of Ptch1. A poly-Ala model was derived using the NPC1 structure as the initial model (PDB code 3JD8) in COOT (77) . Sequence assignment was guided mainly by bulky residues such as Phe, Tyr, Trp, and Arg. The chemical properties of amino acids were taken into consideration to facilitate model building. The glycosylation sites predicted in UniProt were used for model validation. One or two N-acetylglucosamine moieties were built to each site based on the densities. The crystal structure of ShhN (PDB code 4C4M) was docked into the map for Ptch1-ShhN complex and adjusted manually in COOT. For the Ptch1-WT and Ptch1-3M, the structural model of Ptch1 from the complex was fitted into the corresponding maps followed by manual adjustment.
All structure refinements were carried out by PHENIX (78) in real space with secondary structure and geometry restraints. Overfitting of the models was monitored by refining the model against one of the two independent half-maps and testing the refined model against the other map (79).
MBP-mediated pull-down assay
For pull-down assays, the Ptch1 and MBP-ShhN, WT or indicated variants, were incubated with amylose resin resuspended in 200 ml of buffer containing 25 mM Tris pH 8.0, 150 mM NaCl, and 0.06% digitonin or the indicated detergents at concentration of their respective 2× CMC at 4°C for~1 hour. Then the mixture was spun down at 500g for 3 min. After removing the supernatant, the resin was extensively rinsed with the assay buffer to remove unbound proteins. Finally the resin was resuspended in 200 ml of buffer, out of which 20 ml was applied to SDS-PAGE analysis followed by Coomassie blue staining.
In the assay reported in Fig. 3C , all the indicated Ptch1 and MBP-ShhN variants were applied at concentrations of~0.15 mg/ml. In the titration pull-down assay reported in Fig. 5B , ShhN was used at~0.15 mg/ml, while Ptch1 was serially diluted fourfold at concentrations of~0.60, 0.15,~0.04, and~0.01 mg/ml, respectively. In the assay to test the effects of different detergents on the complex formation, the molar ratio of the two proteins was approximately 1:1 with Ptch1 and MBP-ShhN at concentrations of~0.15 and 0.08 mg/ml, respectively.
